Woods-Burnham Leanne, Basu Anamika, Cajigas-Du Ross Christina K, Love Arthur, Yates Clayton, De Leon Marino, Roy Sourav, Casiano Carlos A
Department of Basic Sciences, Center for Health Disparities and Molecular Medicine, Loma Linda University School of Medicine, Loma Linda, California.
Department of Biology and Center for Cancer Research, Tuskegee University, Tuskegee, Alabama.
Prostate. 2017 Dec;77(16):1601-1608. doi: 10.1002/pros.23437. Epub 2017 Oct 14.
Understanding how biological factors contribute to prostate cancer (PCa) health disparities requires mechanistic functional analysis of specific genes or pathways in pre-clinical cellular and animal models of this malignancy. The 22Rv1 human prostatic carcinoma cell line was originally derived from the parental CWR22R cell line. Although 22Rv1 has been well characterized and used in numerous mechanistic studies, no racial identifier has ever been disclosed for this cell line. In accordance with the need for racial diversity in cancer biospecimens and recent guidelines by the NIH on authentication of key biological resources, we sought to determine the ancestry of 22RV1 and authenticate previously reported racial identifications for four other PCa cell lines.
We used 29 established Ancestry Informative Marker (AIM) single nucleotide polymorphisms (SNPs) to conduct DNA ancestry analysis and assign ancestral proportions to a panel of five PCa cell lines that included 22Rv1, PC3, DU145, MDA-PCa-2b, and RC-77T/E.
We found that 22Rv1 carries mixed genetic ancestry. The main ancestry proportions for this cell line were 0.41 West African (AFR) and 0.42 European (EUR). In addition, we verified the previously reported racial identifications for PC3 (0.73 EUR), DU145 (0.63 EUR), MDA-PCa-2b (0.73 AFR), and RC-77T/E (0.74 AFR) cell lines.
Considering the mortality disparities associated with PCa, which disproportionately affect African American men, there remains a burden on the scientific community to diversify the availability of biospecimens, including cell lines, for mechanistic studies on potential biological mediators of these disparities. This study is beneficial by identifying another PCa cell line that carries substantial AFR ancestry. This finding may also open the door to new perspectives on previously published studies using this cell line.
了解生物因素如何导致前列腺癌（PCa）健康差异需要在这种恶性肿瘤的临床前细胞和动物模型中对特定基因或途径进行机制功能分析。22Rv1人前列腺癌细胞系最初源自亲本CWR22R细胞系。尽管22Rv1已得到充分表征并用于众多机制研究，但该细胞系从未披露过种族标识符。根据癌症生物样本中对种族多样性的需求以及美国国立卫生研究院（NIH）关于关键生物资源认证的最新指南，我们试图确定22RV1的血统，并验证先前报道的其他四种PCa细胞系的种族识别情况。
我们使用29个已确立的祖先信息标记（AIM）单核苷酸多态性（SNP）进行DNA血统分析，并为一组五个PCa细胞系（包括22Rv1、PC3、DU145、MDA-PCa-2b和RC-77T/E）确定祖先比例。
我们发现22Rv1具有混合遗传血统。该细胞系的主要祖先比例为0.41西非（AFR）和0.42欧洲（EUR）。此外，我们验证了先前报道的PC3（0.73 EUR）、DU145（0.63 EUR）、MDA-PCa-2b（0.73 AFR）和RC-77T/E（0.74 AFR）细胞系的种族识别情况。
考虑到与PCa相关的死亡率差异对非裔美国男性影响尤为严重，科学界仍有责任使生物样本（包括细胞系）的可用性多样化，以便对这些差异的潜在生物介质进行机制研究。本研究通过鉴定另一种具有大量AFR血统的PCa细胞系而具有益处。这一发现也可能为先前使用该细胞系发表的研究带来新的视角。
